-
Your selected country is
Japan
- Change country/language
-
抗体試薬
- フローサイトメトリー用試薬
-
ウェスタンブロッティング抗体試薬
- イムノアッセイ試薬
-
シングルセル試薬
- BD® AbSeq Assay | シングルセル試薬
- BD Rhapsody™ Accessory Kits | シングルセル試薬
- BD® Single-Cell Multiplexing Kit | シングルセル試薬
- BD Rhapsody™ Targeted mRNA Kits | シングルセル試薬
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit | シングルセル試薬
- BD Rhapsody™ TCR/BCR Profiling Assays (VDJ Assays) | シングルセル試薬
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
-
細胞機能評価のための試薬
-
顕微鏡・イメージング用試薬
-
細胞調製・分離試薬
-
- BD® AbSeq Assay | シングルセル試薬
- BD Rhapsody™ Accessory Kits | シングルセル試薬
- BD® Single-Cell Multiplexing Kit | シングルセル試薬
- BD Rhapsody™ Targeted mRNA Kits | シングルセル試薬
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit | シングルセル試薬
- BD Rhapsody™ TCR/BCR Profiling Assays (VDJ Assays) | シングルセル試薬
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- Japan (Japanese)
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Pharmingen™ PE Rat Anti-Human Clec9A (CD370)
クローン 3A4/Clec9A (also known as 20/05-3A4 or 3A4)
(RUO)Multicolor flow cytometric analysis of human Clec9a expression on dendritic cell subsets from human peripheral blood mononuclear cells. Human peripheral blood mononuclear cells (PBMC) were stained with either PE Rat IgG2a, κ Isotype Control (Cat. No. 553930; Left Panel) or PE Rat Anti-Human Clec9A (CD370) antibody (Cat. No. 563488; Right Panel). The cells were also stained with FITC Mouse Anti-Human HLA-DR (Cat No. 555811), BD Horizon™ BV711 Mouse Anti-Human CD141 (Cat. No. 563155) and a Lineage cocktail comprised of BD Horizon™ V450-conjugated Mouse Anti-Human CD3 (Cat. No. 560366), Mouse Anti-Human CD14 (Cat. No. 560350), Mouse Anti-Human CD19 (Cat. No. 560354) and Mouse Anti-Human CD56 (Cat. No. 560361) antibodies. Two-color flow cytometric dot plots show the correlated expression patterns of Clec9A (CD370) (or Ig Isotype control staining) versus CD141 for Lineage-negative, HLA-DR-positive gated events with the forward and side light-scatter characteristics of viable leucocytes. Flow cytometric analysis was performed using a BD LSRFortessa™ Flow Cytometer System.
BD Pharmingen™ PE Rat Anti-Human Clec9A (CD370)
Regulatory Statusの凡例
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation and Storage
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
関連製品
The 3A4/Clec9A monoclonal antibody specifically binds to human Clec9A (C-type lectin domain family member 9A). Clec9A is a type II transmembrane glycoprotein with a single extracellular C-type lectin domain. Clec9A is also known as CD370 and DNGR1 (Dendritic cell natural killer lectin group receptor 1). Clec9A is selectively expressed on CD141+ myeloid dendritic cells. Clec9A reportedly functions as an endocytic receptor for necrotic cells. It can mediate the cross-presentation of dead-cell associated antigens by dendritic cells in a Syk-dependent manner. The 3A4 antibody reportedly crossreacts with peripheral blood dendritic cells form Pigtail macaques (Macaca nemestrina).
Development References (6)
-
Caminschi L, Proietto AL, Ahmet F, et al. The dendritic cell subtype restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood. 2008; 112(8):3264-3273. (Immunogen: Flow cytometry). View Reference
-
Clark HF, Gurney AL, Abaya E, et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003; 13(10):2265-2270. (Biology). View Reference
-
Huysamen C, Willment JA, Dennehy KM, Brown GD. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes. J Biol Chem. 2008; 283(24):16693-16701. (Biology). View Reference
-
Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010; 207(6):1247-1260. (Clone-specific: Flow cytometry). View Reference
-
Sancho D, Mourão-Sá D, Joffre OP, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008; 118(6):2098-2110. (Biology). View Reference
-
Zhang JG, Czabotar PE, Policheni AN, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012; 36(4):646-657. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Report a Site Issue
This form is intended to help us improve our website experience. For other support, please visit our Contact Us page.